TrialStudy of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
Trial details
- Registry ID
- NCT03767348
- Phase
- Phase 2
REPL
Replimune, Inc.
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
6Trials in this database
7Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceStudy Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
Trial details
- Registry ID
- NCT04050436
- Phase
- Phase 2
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Trial details
- Registry ID
- NCT05733598
- Phase
- Phase 2
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Trial details
- Registry ID
- NCT05733611
- Phase
- Phase 2
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Trial details
- Registry ID
- NCT06264180
- Phase
- Phase 3
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Trial details
- Registry ID
- NCT06581406
- Phase
- Phase 2, Phase 3
Latest recorded trial changes
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180 · Replimune, Inc.
Primary completion date changed
− Before
1 Jan 2029
+ After
30 Sep 2030
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348 · Replimune, Inc.
Primary completion date changed
− Before
Dec 2025
+ After
Jun 2028
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
NCT05733611 · Replimune, Inc.
Actual enrollment increased by 1 participants
− Before
4 participants (actual)
+ After
5 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
1 Jan 2027
+ After
18 Aug 2025
Recruitment status changed
− Before
Active not recruiting
+ After
Terminated
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348 · Replimune, Inc.
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting